RAPID: Subtyping and Identifying Shared Genomic Sequences of SARS-CoV-2 (COVID-19)

  • Funded by National Science Foundation (NSF)
  • Total publications:1 publications

Grant number: 2030541

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2021
  • Known Financial Commitments (USD)

    $199,705
  • Funder

    National Science Foundation (NSF)
  • Principal Investigator

    Yuanfang Guan
  • Research Location

    United States of America
  • Lead Research Institution

    University of Michigan Ann Arbor
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen genomics, mutations and adaptations

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Biological Sciences - People are threatened by an unprecedented pandemic: COVID-19 (caused by SARS-CoV-2). This virus is now threatening not only physical health, but also psychology, education, economy, and every corner of the infrastructure of society. So far, there is no treatment for this disease, while vaccines and neutralizing antibodies are perceived as one of the eventual solutions to this crisis. A critical piece of knowledge supporting vaccine and antibody development is understanding the genome of this virus. What is the common sequence shared among the SARS-CoV-2 strains across the globe? What are the subtypes? Are the genome variances overlapping with important genomic regions for vaccine design? Using state of the art machine learning approaches, this research will identify the shared, representative sequence across SARS-CoV-2 strains and group them by major types. This project will connect this information to the important genomic regions identified in the literature that can be used for vaccines, and thereby continuously inform the ongoing effort of vaccine development, antibody selection, and therapeutic development. The research from this study would provide society benefits through monthly updates onto web interfaces that allow the vaccine developers, the biomedical research community as well as the general public to conveniently get access to the above information. This project will support training of a graduate student in bioinformatics and provide outreach opportunities to K-12 students and the public.

This work will be a continuous effort to monthly subtype SARS-CoV-2 strains and update the shared sequences of SARS-CoV-2, in order to facilitate vaccine development and antibody design. Specifically, this research will be focusing on three objectives: 1) identifying and updating the common sequences of SARS-CoV-2 by forcing the common sequence to have the minimal evolutionary distance with all strains, or covering as many sequences as possible 2) subtyping the SARS-CoV-2 strains into major groups, which will be important to inform treatment, management and prevention measures; 3) connecting the subtyped and common genomic sequences of SARS-CoV-2 to epitopes identified in the literature. To develop vaccines or neutralizing antibody treatment, it is critical that the major variations are covered and considered. The algorithms and visualization tools will overlay the curated list of potential epitopes on top of the subtypes and the shared sequence of the virus genomes, and directly support the effort of vaccine and antibody development. This RAPID award is made by the Systematics and Biodiversity Science Cluster in the Division of Environmental Biology, using funds from the Coronavirus Aid, Relief, and Economic Security (CARES) Act.

This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

Publicationslinked via Europe PMC

Last Updated:an hour ago

View all publications at Europe PMC

IRE1α: a gatekeeper of chemotherapy-induced immunogenicity in triple-negative breast cancer.